Trastuzumab Deruxtecan-Induced Interstitial Lung Disease
WEBBackground and objective: Trastuzumab deruxtecan (T-DXd) is a novel anti-ERBB2 antibody drug conjugate that appears to be associated with an increased risk of lung toxicity. We performed a systematic review to describe the incidence, severity, and management of T-DXd-induced interstitial lung disease (ILD) or pneumonitis.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Detecting and Managing T-DXd–Related Interstitial Lung Disease…
WEBMay 19, 2023 · Both anti-Trop2 datopotamab deruxtecan 8 and the anti-HER3 patritumab deruxtecan 9 are indeed capable of inducing ILD, suggesting that the pulmonary toxicity of T-DXd may represent an off-target toxicity, unrelated to the targeting of HER2.
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan …
WEBAug 30, 2023 · ILD has been identified as an adverse event of special interest with T-DXd and occurs in approximately 10% to 14% of breast cancer patients treated with the drug [1, 2, 3, 4]. If not effectively identified and treated, T-DXd-related ILD can be fatal.
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease…
WEBJun 27, 2022 · Trastuzumab deruxtecan (T-DXd) is a novel anti-ERBB2 antibody drug conjugate that appears to be associated with an increased risk of lung toxicity. We performed a systematic review to describe the incidence, severity, and management of T-DXd-induced interstitial lung disease (ILD) or pneumonitis.
Successful Trastuzumab-Deruxtecan Rechallenge After …
WEBHere, we describe a case of successful rechallenge with T-DXd after CTCAE grade 2 treatment-induced ILD. After discontinuation of T-DXd, ILD was treated with steroids until complete resolution. Given the initial beneficial antitumor response, retreatment was discussed during disease progression.
Pooled analysis of drug-related interstitial lung disease and/or ...
WEBIntroduction: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. Methods: Patients who received T …
Optimizing treatment management of trastuzumab deruxtecan …
WEBAug 11, 2022 · This review discusses the management of common AEs and AEs of special interest in patients with HER2-positive unresectable/metastatic breast cancer, including nausea and vomiting, neutropenia, infusion-related reactions, alopecia, fatigue, ILD/pneumonitis, and left ventricular dysfunction.
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T …
WEBMay 1, 2022 · Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an adverse event associated with T-DXd; in most cases, it is low grade (grade ≤ 2) and can be treated effectively but may develop to be fatal in some instances.
WEBENHERTU® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019. WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. See full prescribing...
Skip to content